NCT00120393 - Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

HIV Infections

Interventions

DRUG

atazanavir/ritonavir +2 NRTIs (immediate Switch Group)

Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.

DRUG

LPV/r +2 NRTIs (Delayed/optional Switch Group)

Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.

Trial Locations (14)

Local Institution, Phoenix

Local Institution, Bakersfield

Local Institution, Los Angeles

Local Institution, San Francisco

Local Institution, Miami

Local Institution, Boston

Local Institution, New York

Local Institution, Cincinnati

Local Institution, Portland

Local Institution, Philadelphia

Local Institution, Columbia

Local Institution, Dallas

Local Institution, Hamilton

Local Institution, Montreal